CarlosCRamosMD

Clinical Trials

• CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL Start of enrollment: 2009 Feb 01

  Active, not recruiting

  Phase 1

• T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL Start of enrollment: 2009 Jul 01

  Active, not recruiting

  Phase 1

• Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT Start of enrollment: 2009 Apr 01

  Active, not recruiting

  Phase 1

• Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL Start of enrollment: 2009 Jul 01

  Recruiting

  Phase 1

• Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) Start of enrollment: 2011 Oct 03

  Withdrawn

  Phase 1

• Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Start of enrollment: 2012 Feb 01

  Completed

  Phase 1

• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) Start of enrollment: 2014 Feb 01

  Recruiting

  Phase 1

• Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) Start of enrollment: 2014 Apr 01

  Active, not recruiting

  Phase 1

• CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) Start of enrollment: 2020 Jun 22

  Recruiting

  Phase 1

• Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas Start of enrollment: 2020 Sep 16

  Recruiting

  Phase 1

• Join now to see all